Market News & Trends
Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan…
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 in Advanced Solid Tumors
Agenus Inc. recently announced the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors. The dose-escalation and expansion…
Kymanox Announces First Fellow Position
Kymanox Corporation recently announced Izi Bruker, PhD, MPH, ASQ has been named as the first Fellow of Kymanox. This highly distinguished honor is reserved for…
SciSparc Signs Clinical Trial Agreement With Yale University to Conduct Phase 2b Trial in Tourette Syndrome
SciSparc Ltd. recently announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase 2b clinical trial…
Starton Therapeutics Reports Positive Results From Phase 1 Study Evaluating Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the company’s continuous delivery….
Nanoform & Pharmanovia to Breathe New Life Into Iconic Medicines
Nanoform Finland Plc. recently announced it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets…..
TFF Pharmaceuticals Expands R&D Operations With New Austin Facility
TFF Pharmaceuticals, Inc. recently announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin,…
Xequel Bio Announces Positive Results From Phase 1b Study for Novel aCT1 Ophthalmic Solution
Xequel Bio, Inc. recently announced positive results from its Phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in…
US Alliance Pharma Acquires UK-Based LGC’s Drug Development Solutions Business
Alliance Pharma recently closed on the purchase of Drug Development Solutions (DDS) from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc., a leading global investment….
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient
Comera Life Sciences Holdings, Inc. recently announced favorable topline results from its recently completed SEQURUS-1 study. The results of this preclinical study provide supportive evidence…
Evonik Now Offers Enteric-Protected Ready-to-Fill Capsules – EUDRACAP- in IPEC-GMP Quality
Evonik’s EUDRACAP enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP enteric are….
Roquette Expands PEARLITOL SD Mannitol Range for Highly Sensitive APIs
Roquette recently announced the addition of a new grade to its PEARLITOL SD mannitol range for direct compression – PEARLITOL 150 SD. Developed specifically for….
ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses
ABL recently announced its partnership with KaliVir Immunotherapeutics in which ABL will manufacture KaliVir’s oncolytic viruses for its….
Gerresheimer Awarded EcoVadis Gold for Sustainable Corporate Management for the First Time
Gerresheimer has been awarded the gold medal for the first time by EcoVadis, one of the leading providers of sustainability rankings, for the successful implementation…
Agarose Bead Technologies Triples its Production Capacity With Major Manufacturing Expansion
Agarose Bead Technologies (ABT) plans a major expansion of its manufacturing capabilities, tripling its production capacity to meet the global demand for agarose resins. With…
Immunocore Announces Dosing of First Patient With ImmTAV Bispecific for HIV
Immunocore Holdings plc recently announced the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific…
MediWound Announces Positive Initial Data From Phase 1/2 Study for the Treatment of Basal Cell Carcinoma
MediWound Ltd. recently announced positive initial data from 11 patients in its ongoing open-label Phase 1/2 study of MW005 for the treatment of low-risk Basal…
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Acer Therapeutics & Relief Therapeutics Announce China National Intellectual Property Administration Issued Utility Model Patent
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the China National Intellectual Property Administration (CNIPA) issued Electronic Patent Certificate ZL202122004991.9 on May…
Sirio Pharma Announces Agreement to Acquire Best Formulations
Sirio Pharma Co., Ltd. – the global nutraceutical contract development and manufacturing organization (CDMO) – and Best Formulations, Inc. recently announced that they have entered…
